Smith & Nephew (SN1N) Stock Price & Analysis
SN1N Stock Chart & Stats
- Day’s Range
- MXN 267.33 - MXN 267.33
- 52-Week Range
- MXN 256.55 - MXN 267.33
- Previous Close
- MXN 267.33
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- MXN 233.31B
- Enterprise Value
- MXN 12.08B
- Total Cash (Recent Filing)
- MXN 757.91M
- Total Debt (Recent Filing)
- MXN 3.80B
- Price to Earnings (P/E)
- 19.5
- Beta
- 0.03
- Next Earnings
- Feb 23, 2027 (Est.)
- EPS Estimate
- 10.25
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 2.87%
Bulls Say, Bears Say
Bulls Say
Margin Expansion And Efficiency
Improving margins and savings achieved ahead of schedule indicate stronger operating discipline and a more efficient cost base. If sustained, these gains can protect profitability against moderate revenue pressure, support reinvestment, and improve cash generation over the next several quarters.
Innovation And Product Momentum
A consistent launch pipeline and progress in robotics expand Smith & Nephew’s technology offering and support future procedure adoption. New products can strengthen surgeon engagement, address portfolio gaps, and create durable growth opportunities across orthopaedics and adjacent specialties.
Improved Cash Generation And Manageable Leverage
Recent cash-flow improvement provides greater capacity to fund product development, acquisitions, dividends, and buybacks without relying excessively on new borrowing. Leverage remains within management’s stated target, preserving financial flexibility while the company executes its growth and efficiency plans.
Bears Say
Lower Revenue Growth Outlook
The guidance reduction signals that near-term commercial momentum is weaker than previously expected, limiting the pace at which fixed costs and innovation investments can be leveraged. Slower growth also increases dependence on efficiency savings to deliver profit targets and raises execution pressure.
Reimbursement And Portfolio Friction
Reimbursement changes and portfolio gaps are directly constraining procedure-related demand and delaying recovery in important franchises. These issues may require product adaptation, stronger clinical and payer support, or additional commercial investment, making the revenue recovery path less certain.
Uneven Cash Conversion And Rising Net Debt
Although absolute cash generation has improved, inconsistent conversion from earnings and higher net debt reduce financial flexibility. Acquisitions, buybacks, dividends, and investment are consuming cash while operating performance is being repaired, increasing sensitivity to delays in recovery or further spending needs.
SN1N FAQ
What was Smith & Nephew’s price range in the past 12 months?
What is Smith & Nephew’s market cap?
When is Smith & Nephew’s upcoming earnings report date?
How were Smith & Nephew’s earnings last quarter?
Is Smith & Nephew overvalued?
Does Smith & Nephew pay dividends?
What is Smith & Nephew’s EPS estimate?
How many shares outstanding does Smith & Nephew have?
What happened to Smith & Nephew’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Smith & Nephew?
What is the TipRanks Smart Score and how is it calculated?
Smith & Nephew Stock Smart Score
Company Description
Smith & Nephew
Smith & Nephew plc, along with its subsidiaries, operates globally as a developer, manufacturer, marketer, and seller of medical technology. Its orthopaedic division offers knee implants for replacement procedures and hip implants for joint reconstruction. This segment also provides trauma and extremities products, including internal and external fixation devices crucial for stabilizing severe fractures and correcting deformities. In the sports medicine field, the company furnishes surgeons with comprehensive joint repair solutions. These encompass specialized instruments, advanced technologies, and implants necessary for minimally invasive joint surgeries, addressing soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. Additionally, its arthroscopic enabling technologies support surgical visualization and intervention inside joints, comprising fluid management equipment, high-definition cameras, digital image capture systems, scopes, light sources, and monitors. It also supplies radiofrequency, electromechanical, and mechanical tissue resection devices, along with hand instruments for removing damaged tissue, and provides ear, nose, and throat (ENT) solutions. Furthermore, Smith & Nephew delivers sophisticated advanced wound management solutions. This category features products for the treatment and prevention of acute and chronic wounds, including leg, diabetic, and pressure ulcers, burns, and post-operative wounds. Its offerings extend to advanced wound bioactives, incorporating biologics and other active technologies for debridement, dermal repair, and regeneration, as well as regenerative medicine products like skin, bone graft, and articular cartilage substitutes. The advanced wound devices portfolio includes traditional and single-use negative pressure wound therapy systems, alongside hydrosurgery devices. Primarily serving healthcare providers, Smith & Nephew plc was founded in 1856 and maintains its corporate headquarters in Watford, United Kingdom.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Deepak S. Nath
- Employees
- 18,362
- Website
- www.smith-nephew.com
- Address
- Building 5 Croxley Park Hatters Lane, Watford, HRT, WD18 8YE, GB
Smith & Nephew (SN1N) Earnings & Revenues
SN1N Earnings Call
Earnings Call SentimentNeutral
The call balanced clear operational and financial progress (strong trading profit, margin expansion, sizeable efficiency savings, product launches and robotics/innovation momentum) against a disappointing top-line start driven by U.S. Orthopaedics and Advanced Wound Bioactives reimbursement/market frictions. Management lowered revenue growth guidance for 2026 to around 4% but maintained profit, cash flow and ROIC targets by accelerating savings and offsetting tariff impacts. Execution risk remains in Orthopaedics set deployments, skin substitute reimbursement adaptation and near-term cash timing, while multiple innovation and commercial levers are positioned to drive recovery in H2 and into 2027.
View all MX:SN1N earnings summariesSN1N Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 3 | 2 |
| Technical Analysis | 2 | 2 | 2 |
| Moving Averages | 11 | 1 | 0 |